Cas:27257-15-4 1-Methyl-1H-pyrrolo[2,3-b]pyridine manufacturer & supplier

Chemical Name:1-Methyl-1H-pyrrolo[2,3-b]pyridine

CAS.NO:27257-15-4

Synonyms:1H-Pyrrolo[2,3-b]pyridine,1-methyl;1-Methyl-7-azaindole;N1-Methyl-7-azaindole;1-Methyl-7-Azaindole;N-methyl-1H-pyrrolo[2,3-b]pyridine;1-Methyl-1H-pyrrolo[2,3-b]pyridine;N-methyl-7-azaindole

Molecular Formula:C₈H₈N₂

Molecular Weight:132.16300

HS Code:2933990090

Physical and Chemical Properties:

Melting point:N/A

Boiling point:254.2ºC at 760 mmHg

Density:1.11g/cm3

Index of Refraction:1.609

PSA:17.82000

Exact Mass:132.06900

LogP:1.57330

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like 1H-Pyrrolo[2,3-b]pyridine,1-methyl chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,N-methyl-7-azaindole physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,1-Methyl-7-Azaindole Use and application,1H-Pyrrolo[2,3-b]pyridine,1-methyl technical grade,usp/ep/jp grade.

Related News: Our collaboration with Mankind demonstrates our commitment towards providing novel, innovative treatment options for efficient diabetes management, Glenmark Pharmaceuticals President, India Formulations, Middle East and Africa Sujesh Vasudevan said. 1-Methyl-1H-pyrrolo[2,3-b]pyridine manufacturer In recent years, China’s bulk drug companies have gradually completed the upgrade of the product structure of bulk raw materials to specialty raw materials and intermediates. The industry’s leading companies have further developed the research and development layout of high-barrier generic pharmaceutical raw materials with multiple patents that have not yet expired. 1-Methyl-1H-pyrrolo[2,3-b]pyridine supplier AstraZeneca Plc said on Monday that its cancer drug met the main goal of delaying the progression of a form of lung cancer. 1-Methyl-1H-pyrrolo[2,3-b]pyridine vendor AstraZeneca Plc said on Monday that its cancer drug met the main goal of delaying the progression of a form of lung cancer. 1-Methyl-1H-pyrrolo[2,3-b]pyridine factory In recent years, China’s bulk drug companies have gradually completed the upgrade of the product structure of bulk raw materials to specialty raw materials and intermediates. The industry’s leading companies have further developed the research and development layout of high-barrier generic pharmaceutical raw materials with multiple patents that have not yet expired.